Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: What next?

Clinical Infectious Diseases

Volumn 50, Issue 6, 2010, Pages 909-911

  Cotton, Mark F ^a   Rabie, Helena ^a   Van Zyl, Gert U ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE;

CLINICAL TRIAL; DRUG COST; DRUG EFFECT; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK REDUCTION; SINGLE DRUG DOSE; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MUTATION, MISSENSE; NEVIRAPINE; PREGNANCY; ZIDOVUDINE;

EID: 77749254690     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650746     Document Type: Note

References (29)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331(18):1173-1180.
2. 2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency viruus infection. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
3. Mofenson L, Taylor AW, Rogers M, et al. Achievements in public health: reduction in perinatal transmission of HIV Infection- United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006;55(21):592-597.
4. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353(9155):773-780.
5. Wiktor SZ, Ekpini E, Karon JM, et al. Shortcourse oral zidovudine for prevention of mofher-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999;353(9155):781-785.
6. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000;343(14):982-991.
7. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354(9181):795-802.
8. Eshleman SH, Mračna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15(15):1951-1957.
9. 9. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351(3):229-240. (Pubitemid 38922817)
10. Lockman S; A5208 Study Team. Lopinavir/ ritonavir+tenofovir/emtricitabine is superior to nevirapine+tenofovir/emtricitabine for women with prior exposure to single-dose nevirapine: A5208 ("OCTANE"). In: Program and abstracts of the 16th Conference on Retrovirology and Opportunistic Infection (Montreal). Alexandria, VA: Foundation for Retrovirology and Human Health, 2009. Abstract 94LB.
11. Mclntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mofher-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009;6(10): el.000172.
12. 12. Chi BH, Sinkala M, Mbewe F, et al. Singledose tenofovir and emtricitabine for reduction of viral resistance to non-nudeoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007;370(9600):1698-1705. (Pubitemid 350100773)
13. Lallemant M, Ngo-Giang-Huong N, Jourdain G, et al. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis 2010; 50:898-908 (in this issue).
14. 14. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351(3):217-228. (Pubitemid 38916040)
15. Van Dyke R, Jourdain G, Shapiro DE, et al. A phase II study of the incidence of nevirapine resistance mutations in HIV-infected Thai women receiving a single intrapartum dose of NVP followed by a postpartum tail of ZDV/ ddl or ZDV/ddl/LPV/r: IMPAACT P1032. In: Program and abstracts of the 16th Conference on Retrovirology and Opportunistic Infection (Montreal). Alexandria, VA: Foundation for Retrovirology and Human Health, 2009. Abstract 95aLB.
16. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7:402-409.
17. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007;9(1):25-39.
18. Firnhaber C, Reyneke A, Schulze D, et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J 2008;98(7):541-544.
19. 19. Pirillo MF, Bassani L, Germinarlo EA, et al. Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol 2007; 79(12):1797-1801. (Pubitemid 350006301)
20. 10. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002;288(2):189-198. (Pubitemid 34755279)
21. 21. Sibeko S, Moodley J. Healthcare attendance patterns by pregnant women in Durban, South Africa. SA Fam Pract 2006; 48(10): 17a-17e. (Pubitemid 46261606)
22. Pattinson RC, Rossouw L. The unbooked mother at Tygerberg Hospital: a prospective controlled study. S Afr Med J 1987; 71(9): 559-560.
23. 23. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent motherto-child HIV transmission in Botswana. AIDS 2006;20(9):1281-1288. (Pubitemid 44030377)
24. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following singledose nevirapine in a PMTCT Cohort. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San. Fransisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
25. UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report. 2009.
26. 26. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356(2):135-147. (Pubitemid 46089674)
27. Palumbo P, Violari A, Lindsey J, et al. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. In: Program and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). Stockholm: International AIDS Society, 2009. Abstract LBPEB12.
28. Coovadia A, Abrams E, Strehlau R, et al. Randomized clinical trial of switching to nevirapine-based therapy for infected children exposed to nevirapine prophylaxis. In: Program and abstracts of the 5th International AIDS Society Conference on HTV Pathogenesis, Treatment and Prevention (Cape Town, South Africa). Stockholm: International AIDS Society, 2009. Abstract MOAB103.
29. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008;359(2):119-129.